Morgan Stanley initiates coverage on Hengrui Pharmaceuticals stock with Overweight rating

Morgan Stanley has initiated coverage on Jiangsu Hengrui Pharmaceuticals (1276:HK) with an Overweight rating and a HK$78.00 price target, citing the company's broad and well-balanced product pipeline across oncology, metabolic, and other therapeutic areas. The investment bank anticipates a robust approval pipeline, projecting 47 new drug approvals from 2025 to 2027, including competitive HER2 ADC and GLP-1 candidates, and highlights significant global expansion opportunities driven by Hengrui's successful out-licensing deals, which have aggregated US$15 billion since 2018.

Analysis

Morgan Stanley has initiated coverage on Jiangsu Hengrui Pharmaceuticals (1276:HK) with a bullish outlook, issuing an Overweight rating and a HK$78.00 price target. The positive thesis is anchored in Hengrui's diversified product pipeline, which the bank describes as one of the most well-balanced among Chinese biopharma firms, spanning oncology, metabolic, and immunology. A key driver for this outlook is the company's dense approval schedule, with a projected 47 New Drug Application (NDA) or Biologics License Application (BLA) approvals forecasted between 2025 and 2027. Specific assets of note include a recently approved HER2 ADC and competitive late-stage GLP-1 candidates. The analysis further highlights a significant international growth vector, with the US$1.47 trillion global pharmaceutical market being 6.6 times larger than China's domestic market. Hengrui's capacity for global expansion is supported by a strong track record of securing 14 out-licensing deals valued at an aggregate US$15 billion since 2018, with expectations of more agreements as global firms increase sourcing from China.

Key Decisions for Investors

• Given the Overweight rating and specific price target, investors with an appetite for emerging market biotech may consider the stock for a long position, viewing the analysis as a strong institutional endorsement.
• It is critical to monitor the company's execution against its ambitious approval pipeline, specifically the 47 projected NDA/BLA approvals through 2027, as meeting these targets is fundamental to the valuation thesis.
• Future out-licensing agreements should be treated as significant positive catalysts, as they validate the pipeline's value and provide non-dilutive capital for further development and expansion.